Antivir Ther. 2015;20(1):1-10. doi:

Antivir Ther. 2015;20(1):1-10. doi: 10.3851/IMP2851. Epub 2014 Aug 26.
Antiviral therapy for human rabies.
Appolinario CM1, Jackson AC.
Author information

Abstract
Human rabies is virtually always fatal despite numerous attempts at aggressive therapy. Most survivors received one or more doses of rabies vaccine prior to the onset of the disease. The Milwaukee Protocol has proved to be ineffective for rabies and should no longer be used. New approaches are needed and an improved understanding of basic mechanisms responsible for the clinical disease in rabies may prove to be useful for the development of novel therapeutic approaches. Antiviral therapy is thought to be an important component of combination therapy for the management of human rabies, and immunotherapy and neuroprotective therapy should also be strongly considered. There are many important issues for consideration regarding drug delivery to the central nervous system in rabies, which are in part related to the presence of the blood-brain barrier and also the blood-spinal cord barrier. Ribavirin and interferon-α have proved to be disappointing agents for the therapy of rabies. There is insufficient evidence to support the continued use of ketamine or amantadine for the therapy of rabies. Minocycline or corticosteroids should not be used because of concerns about aggravating the disease. A variety of new antiviral agents are under development and evaluation, including favipiravir, RNA interference (for example, small interfering [si]RNAs) and novel targeted approaches, including interference with viral capsid assembly and viral egress.

結果 (中文) 1:

Antivir 那里。2015; 20 （1）︰ 1-10。doi: 10.3851/IMP2851。Epub 2014 Aug 26。抗病毒治疗的人类感染疯狗症。Appolinario CM1，杰克逊交流。作者信息摘要Human rabies is virtually always fatal despite numerous attempts at aggressive therapy. Most survivors received one or more doses of rabies vaccine prior to the onset of the disease. The Milwaukee Protocol has proved to be ineffective for rabies and should no longer be used. New approaches are needed and an improved understanding of basic mechanisms responsible for the clinical disease in rabies may prove to be useful for the development of novel therapeutic approaches. Antiviral therapy is thought to be an important component of combination therapy for the management of human rabies, and immunotherapy and neuroprotective therapy should also be strongly considered. There are many important issues for consideration regarding drug delivery to the central nervous system in rabies, which are in part related to the presence of the blood-brain barrier and also the blood-spinal cord barrier. Ribavirin and interferon-α have proved to be disappointing agents for the therapy of rabies. There is insufficient evidence to support the continued use of ketamine or amantadine for the therapy of rabies. Minocycline or corticosteroids should not be used because of concerns about aggravating the disease. A variety of new antiviral agents are under development and evaluation, including favipiravir, RNA interference (for example, small interfering [si]RNAs) and novel targeted approaches, including interference with viral capsid assembly and viral egress.

結果 (中文) 3:

AntiVir疗法。2015；20（1）：1-10。关键词：10.3851/imp2851。收稿日期8月26日2014。人狂犬病的抗病毒治疗。appolinario CM1，Jackson AC.作者信息摘要人类的狂犬病几乎是致命的，尽管在积极治疗的无数次尝试。大多数幸存者在发病前接受了一个或多个剂量的狂犬病疫苗。密尔沃基协议已被证明是无效的狂犬病，并应不再使用。新的方法是必要的，一种改进的理解，负责在狂犬病的临床疾病的基本机制可能被证明是有用的新的治疗方法的发展。抗病毒治疗被认为是治疗人类狂犬病的联合治疗的重要组成部分，并应考虑免疫治疗和神经保护治疗。有许多重要的问题，考虑到药物输送到中枢神经系统的狂犬病，这是在血脑屏障的存在和血脊髓屏障的一部分。Ribavirin和干扰素-α已被证明是令人失望的狂犬病的治疗剂。没有足够的证据支持继续使用氯胺酮或金刚烷胺对狂犬病的治疗。米诺环素或糖皮质激素不应该因为对疾病加重的担忧。各种新型抗病毒药物的开发和评估，包括favipiravir，RNA干扰（例如，小干扰[Si] RNA）和新的有针对性的方法，包括干扰病毒衣壳的组装和病毒的出口。